PolyNovo Limited
ABN 96 083 866 862
2/320 Lorimer Street, Port Melbourne VIC 3207
Tel: +61 3 8681 4050 Fax: +61 3 8681 4099

28 December 2015

PolyNovo's US FDA approval

The Board of PolyNovo Limited ('PolyNovo') is excited to announce that the US FDA has granted regulatory approval for its Biodegradable Temporising Matrix (BTM) for use in reconstructive and surgical wounds. The 510(k) approval allows PolyNovo to sell the BTM in the USA.

The corporate office of PolyNovo is closed for Christmas/New Year and the company will provide further details on January 4th.

The CEO Paul Brennan said *"This is a very significant milestone for PolyNovo. FDA approval means we are now a commercial enterprise with access to the largest reimbursed dermal matrix market in the world."*

Further information:

David Williams
Chairman
Mobile: + 61 414 383 593
Email: dwilliams@kidder.com.au

Paul Brennan
Chief Executive Officer
Direct: +61 3 8681 4055
Email: paul.b@polynovo.com